# Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis

> **NCT03691493** · PHASE2 · COMPLETED · sponsor: **Emory University** · enrollment: 36 (actual)

## Conditions studied

- Anatomic Stage IV Breast Cancer AJCC v8
- Estrogen Receptor Positive
- HER2/Neu Negative
- Metastatic Breast Carcinoma
- Metastatic Malignant Neoplasm in the Bone
- Progesterone Receptor Positive
- Prognostic Stage IV Breast Cancer AJCC v8

## Interventions

- **DRUG:** Anastrozole
- **DRUG:** Exemestane
- **DRUG:** Fulvestrant
- **DRUG:** Letrozole
- **DRUG:** Palbociclib
- **RADIATION:** Radiation Therapy
- **DRUG:** Tamoxifen

## Key facts

- **NCT ID:** NCT03691493
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-08
- **Primary completion:** 2022-10-13
- **Final completion:** 2022-10-13
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-02-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03691493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03691493, "Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03691493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*